We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Inc.’s (PFE - Free Report) is one of the most well-known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products. This New York-based company is well known for products like Prevnar, Lyrica, Lipitor and Celebrex among others.
However, like many of its peers, PFE is facing generic competition and pricing pressure for several products. Other than that lost alliance revenues, supply shortages in legacy Hospira products, pricing pressure and rising competition are hurting the top-line.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential and performance of new products apart from the usual top-and bottom-line numbers.
The pharma giant has a fairly decent record of earnings surprises. The company’s earnings surpassed expectations in three of the last four quarters while missing in one, resulting in an average positive surprise of 0.79%.
Currently, PFE has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earning Beat: PFE beat fourth quarter earnings which came in at 62 cents while our consensus called for EPS of 56 cents. Earnings rose 32% year over year.
Revenues Beat: Revenues also expectations. Pfizer posted revenues of $13.70 billion, which beat the Zacks Consensus Estimate of $13.61 billion. Revenues rose 1% from the year-ago quarter on a reported basis. On an operational basis, revenues were flat year over year.
2018 Guidance: Revenues are expected in the range of $53.5 billion to $55.5 billion in 2018. The Zacks Consensus Estimate is pegged at $53.72 billion.
Adjusted earnings per share are expected in the range of $2.90 - $3.00 which was above the Zacks Consensus Estimate of $2.77 per share.
Pre-Market Trading: Shares rose more than 2% in pre-market trading.
Check back later for our full write up on this PFE earnings report later!
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks’ has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Pfizer (PFE) Q4 Earnings & Sales Top, 2018 View Upbeat
Pfizer Inc.’s (PFE - Free Report) is one of the most well-known names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products. This New York-based company is well known for products like Prevnar, Lyrica, Lipitor and Celebrex among others.
However, like many of its peers, PFE is facing generic competition and pricing pressure for several products. Other than that lost alliance revenues, supply shortages in legacy Hospira products, pricing pressure and rising competition are hurting the top-line.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential and performance of new products apart from the usual top-and bottom-line numbers.
The pharma giant has a fairly decent record of earnings surprises. The company’s earnings surpassed expectations in three of the last four quarters while missing in one, resulting in an average positive surprise of 0.79%.
Pfizer, Inc. Price and Consensus
Pfizer, Inc. Price and Consensus | Pfizer, Inc. Quote
Currently, PFE has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earning Beat: PFE beat fourth quarter earnings which came in at 62 cents while our consensus called for EPS of 56 cents. Earnings rose 32% year over year.
Revenues Beat: Revenues also expectations. Pfizer posted revenues of $13.70 billion, which beat the Zacks Consensus Estimate of $13.61 billion. Revenues rose 1% from the year-ago quarter on a reported basis. On an operational basis, revenues were flat year over year.
2018 Guidance: Revenues are expected in the range of $53.5 billion to $55.5 billion in 2018. The Zacks Consensus Estimate is pegged at $53.72 billion.
Adjusted earnings per share are expected in the range of $2.90 - $3.00 which was above the Zacks Consensus Estimate of $2.77 per share.
Pre-Market Trading: Shares rose more than 2% in pre-market trading.
Check back later for our full write up on this PFE earnings report later!
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks’ has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 4 crypto-related stocks now >>